This report provides: a summary of the horizon scanning strategy devised to identify newly created or updated records within 2025; an overview of the landscape of clinical trials in remit, the therapeutic areas of the indications based on NICE categories, drug designations, industry sponsors; and gives some high-level conclusions drawing on the themes and patterns identified.
Download PDF